Upexi (UPXI) Competitors $7.93 +0.95 (+13.61%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.93 0.00 (0.00%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPXI vs. GMTX, RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, TARS, and OCULShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), Tarsus Pharmaceuticals (TARS), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Its Competitors Gemini Therapeutics Recursion Pharmaceuticals Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Organon & Co. Alvotech Centessa Pharmaceuticals ImmunityBio Tarsus Pharmaceuticals Ocular Therapeutix Gemini Therapeutics (NASDAQ:GMTX) and Upexi (NASDAQ:UPXI) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk. Do analysts prefer GMTX or UPXI? Upexi has a consensus price target of $15.50, suggesting a potential upside of 95.46%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Upexi 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is GMTX or UPXI more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -135.86%. Gemini Therapeutics' return on equity of -38.78% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Upexi -135.86%-535.19%-122.94% Does the media prefer GMTX or UPXI? In the previous week, Upexi had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Upexi and 0 mentions for Gemini Therapeutics. Upexi's average media sentiment score of 0.98 beat Gemini Therapeutics' score of 0.00 indicating that Upexi is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Upexi Positive Which has more volatility & risk, GMTX or UPXI? Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Comparatively, Upexi has a beta of -0.52, meaning that its stock price is 152% less volatile than the S&P 500. Which has better earnings & valuation, GMTX or UPXI? Upexi has higher revenue and earnings than Gemini Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-59.75Upexi$26M17.88-$23.66MN/AN/A Do institutionals and insiders hold more shares of GMTX or UPXI? 75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 4.4% of Upexi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryUpexi beats Gemini Therapeutics on 8 of the 14 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$409.11M$2.55B$24.33B$9.60BDividend YieldN/A1.59%2.83%4.10%P/E RatioN/A23.1528.3826.04Price / Sales17.8838.7240.38103.40Price / CashN/A41.6425.7858.48Price / Book1.276.626.026.61Net Income-$23.66M$34.55M$197.30M$265.56M7 Day Performance7.89%1.82%1.40%1.95%1 Month Performance18.36%-5.62%-2.53%-0.37%1 Year Performance98.25%37.27%32.76%19.02% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi2.7809 of 5 stars$7.93+13.6%$15.50+95.5%+107.5%$409.11M$26M0.00130GMTXGemini TherapeuticsN/A$59.86-1.4%N/A+22.6%$2.59BN/A-59.8630RXRXRecursion Pharmaceuticals2.5487 of 5 stars$5.52-4.3%$7.00+26.8%-32.8%$2.51B$58.84M-3.10400News CoverageInsider TradeCPRXCatalyst Pharmaceuticals4.8908 of 5 stars$20.23flat$33.20+64.1%+1.6%$2.48B$558.50M12.2680Positive NewsAnalyst DowngradeKNSAKiniksa Pharmaceuticals International2.6925 of 5 stars$33.72+1.0%$41.17+22.1%+28.8%$2.47B$423.24M843.21220Positive NewsInsider TradeOGNOrganon & Co.4.7545 of 5 stars$9.27-1.8%$18.00+94.2%-54.9%$2.45B$6.40B3.454,000Positive NewsALVOAlvotech2.3872 of 5 stars$9.00+12.2%$14.00+55.6%-29.4%$2.42B$491.98M39.131,032News CoverageShort Interest ↓High Trading VolumeCNTACentessa Pharmaceuticals2.1337 of 5 stars$17.59-2.5%$28.10+59.7%+39.4%$2.42B$6.85M-9.83200IBRXImmunityBio2.5144 of 5 stars$2.43-4.7%$10.75+342.4%-44.5%$2.41B$14.74M-5.06590TARSTarsus Pharmaceuticals1.9006 of 5 stars$54.61+0.7%$66.67+22.1%+126.2%$2.29B$182.95M-23.4450News CoveragePositive NewsOCULOcular Therapeutix4.1028 of 5 stars$12.31-2.5%$17.20+39.7%+37.6%$2.20B$56.66M-9.62230 Related Companies and Tools Related Companies GMTX Alternatives RXRX Alternatives CPRX Alternatives KNSA Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives IBRX Alternatives TARS Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPXI) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access